Clinical Trials · NCT07187856
Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus
- Phase
- Phase 2
- Recruitment status
- Not Yet Recruiting
- Sponsor
- ProGen. Co., Ltd.
- Enrollment
- 80
- Start date
- Jan 2026
- Locations
- 1 site, Australia
- Primary endpoint
- Absolute change in HbA1c From Baseline at Week 24